Abstract
Summary
PROTEGO is a Chilean cluster‐randomised crossover trial of vernix caseosa retention to prevent atopic dermatitis.
1383 mother‐infant dyads will be enrolled and followed for atopic dermatitis until 12 months.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureArturo Borzutzky, Carolina Cabalín, Juan Pablo Fraga, Jorge Fabres, Alberto Toso, Marcelo Farías, Maria-Laura Cossio, María José Escalante, Paula Fajuri, Maite Rojas-McKenzie, Magdalena Sande, Rosario Willatt, Carolina Barrientos, Robert J. Boyle
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Atopic Dermatitis
10.1056/nejmra074081 · 2008
Atopic Dermatitis in Latin America: A Roadmap to Address Data Collection, Knowledge Gaps, and Challenges
10.1097/der.0000000000000904 · 2022
The Natural Course of Atopic Dermatitis From Birth to Age 7 Years and the Association With Asthma
2004
Daily Emollient During Infancy for Prevention of Eczema: The BEEP Randomised Controlled Trial
10.1016/s0140-6736(19)32984-8 · 2020
Vernix Caseosa as a Multi‐Component Defence System Based on Polypeptides, Lipids and Their Interactions
10.1007/s00018-005-5260-7 · 2005
Unresolved referenced work
Kept as external metadata until matched
Vernix Caseosa in Neonatal Adaptation
10.1038/sj.jp.7211305 · 2005
Vernix Caseosa: Benefits and Clinical Implications in Neonatal Care; A Study Conducted at Almak Nimr University Hospital, Shendi, Sudan
10.64252/tc1vd872 · 2025
Diagnosing Atopic Dermatitis in Infancy Using Established Diagnostic Criteria: A Cohort Study
10.1111/bjd.19831 · 2022
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
No additional external references are available.